Evommune | Novel Therapies for Chronic Inflammatory Disease

Evommune was founded to discover and develop innovative therapies that target key drivers of chronic inflammatory disease.

Our Approach

We use leading edge science to target the root causes of inflammation.

Our Programs

Advancing a pipeline of differentiated product candidates for chronic inflammatory diseases.

See Our Pipeline

Recent News

October 30, 2025

Evommune Announces Commencement of Initial Public Offering

September 19, 2025

Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress

September 2, 2025

Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

View All

Are you a driven performer ready to make an impact? Join our team!